Director, Immuno-oncology and Cellular Therapy Translational Sciences @ (March 2018 - March 2020)
Principal Scientist, Biomarkers @ (July 2016 - March 2018)
Senior Manager, Diagnostics and Biomarkers @ (November 2015 - June 2016)
Lead Scientist Translational Research @ (September 2014 - October 2015)
Senior Scientist Biomarkers @ (January 2014 - August 2014)
Associate Director, Pharmacology @ (May 2012 - January 2014)
Senior Scientist @ (January 2005 - October 2011)
Scientist @ (July 2004 - December 2004)
Postdoctoral Fellow @ (January 2002 - January 2004)
Michelle Blake Education
University of Washington
Ph.D. (Pathology)
1995-2001
California Polytechnic State University-San Luis Obispo
Bachelor of Science (Biochemistry/Microbiology double major)
1989-1993
Michelle Blake Skills
In vivo tumor models
Cell culture
Microarray Analysis
Flow Cytometry
Immunohistochemistry
Animal surgery
Signal Transduction
Apoptosis
Technical Project Leadership
Drug discovery
Gene Expression Profiling
Fluorescence Microscopy
Antibody validation
In Vivo
Antibodies
Conceptual Modeling
Validation
In Vitro
Cell
Pharmacology
Monoclonal Antibodies
Assay Development
Oncology
Drug Development
CRO
Translational Medicine
Clinical Development
Translational Research
Biomarkers
High Throughput Screening
Immunology
Inflammation
ELISA
Cell Biology
Pharmaceutical Industry
Project Management
Biochemistry
CRO Management
Research
Michelle Blake Summary
Michelle Blake, based in Seattle, WA, US, is currently a Vice President, Translational Sciences at Sonoma Biotherapeutics. Michelle Blake brings experience from previous roles at Shape Therapeutics, Inc., Celgene, Juno Therapeutics, Inc. and Seattle Genetics. Michelle Blake holds a 1995 - 2001 Ph.D. in Pathology @ University of Washington. With a robust skill set that includes In vivo tumor models, Cell culture, Microarray Analysis, Flow Cytometry, Immunohistochemistry and more. Michelle Blake has 2 emails and 2 mobile phone numbers on RocketReach.
Looking for a different Michelle Blake?
Find contact details for 700 million professionals.